China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SHE:300294)

Market Cap	8.58B -36.1%
Revenue (ttm)	1.84B +1.2%
Net Income	3.44M -99.1%
EPS	0.01 -99.1%
Shares Out	504.25M
PE Ratio	2,496.95
Forward PE	25.58
Dividend	0.22 (1.35%)
Ex-Dividend Date	May 20, 2026

Volume	14,582,554
Open	15.33
Previous Close	16.49
Day's Range	15.33 - 17.30
52-Week Range	15.12 - 27.99
Beta	0.22
Analysts	Buy
Price Target	28.00 (+64.61%)
Earnings Date	Aug 21, 2026

About SHE:300294

China Resources Boya Bio-pharmaceutical Group Co.,Ltd engages in the research, development, production, and sale of blood products in China. It offers blood products, such as human serum albumin; human, intravenous, freeze-dried intravenous, hepatitis B, tetanus, and rabies immunoglobulin; and human fibrinogen, prothrombin complex, and coagulation factor VIII. The company also provides compound bone peptide, oxytocin, heparin sodium injection, posterior pituitary, and carboprost tromethamine injection. In addition, it engages in research, devel...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 1,947
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300294

Financial Performance

In 2025, SHE:300294's revenue was 2.06 billion, an increase of 18.69% compared to the previous year's 1.73 billion. Earnings were 112.70 million, a decrease of -71.61%.